Landscape Capital Management L.L.C. bought a new stake in Abivax SA Sponsored ADR (NASDAQ:ABVX – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 30,054 shares of the company’s stock, valued at approximately $4,053,000.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Prosight Management LP bought a new position in Abivax in the fourth quarter valued at about $2,293,000. FORA Capital LLC bought a new stake in shares of Abivax during the fourth quarter worth about $1,060,000. The Manufacturers Life Insurance Company grew its holdings in shares of Abivax by 36.0% during the fourth quarter. The Manufacturers Life Insurance Company now owns 35,532 shares of the company’s stock worth $4,915,000 after purchasing an additional 9,396 shares during the last quarter. Affinity Asset Advisors LLC grew its holdings in shares of Abivax by 40.3% during the fourth quarter. Affinity Asset Advisors LLC now owns 505,000 shares of the company’s stock worth $68,102,000 after purchasing an additional 145,000 shares during the last quarter. Finally, Stifel Financial Corp bought a new stake in shares of Abivax during the fourth quarter worth about $1,380,000. Institutional investors own 47.91% of the company’s stock.
Analyst Upgrades and Downgrades
Several analysts have recently weighed in on ABVX shares. Barclays boosted their price target on Abivax from $142.00 to $148.00 and gave the stock an “overweight” rating in a report on Tuesday, March 24th. Jefferies Financial Group cut Abivax from a “buy” rating to a “hold” rating and reduced their price target for the stock from $160.00 to $90.00 in a report on Tuesday, June 2nd. Wedbush upgraded shares of Abivax from an “underperform” rating to a “neutral” rating and cut their price target for the stock from $110.00 to $90.00 in a report on Tuesday, June 2nd. Oddo Bhf reiterated an “outperform” rating on shares of Abivax in a report on Thursday, April 9th. Finally, Wolfe Research set a $136.00 price objective on Abivax in a report on Wednesday, June 3rd. Twelve research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Abivax presently has a consensus rating of “Moderate Buy” and an average price target of $130.08.
Abivax Price Performance
Shares of ABVX stock opened at $96.55 on Friday. The business’s 50 day simple moving average is $116.01 and its 200 day simple moving average is $119.12. Abivax SA Sponsored ADR has a one year low of $5.69 and a one year high of $148.83. The stock has a market capitalization of $7.69 billion, a PE ratio of -18.53 and a beta of 0.69.
Abivax (NASDAQ:ABVX – Get Free Report) last announced its earnings results on Friday, May 22nd. The company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.94) by $0.23. The company had revenue of $1.56 million during the quarter, compared to the consensus estimate of $0.40 million. As a group, research analysts expect that Abivax SA Sponsored ADR will post -3.4 earnings per share for the current year.
Abivax Company Profile
Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.
Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.
Featured Stories
- Five stocks we like better than Abivax
- Time to Sell? 3 Winners With Fading Technical Momentum
- Why These 2 Hotel Stocks Are Beating Travel Peers
- This Energy Stock Has Quietly Soared 130% in a Year
- 3 ‘Boring’ Dividend Stocks With Tasty Technical Setups
Want to see what other hedge funds are holding ABVX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abivax SA Sponsored ADR (NASDAQ:ABVX – Free Report).
Receive News & Ratings for Abivax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abivax and related companies with MarketBeat.com's FREE daily email newsletter.
